Provided by Tiger Trade Technology Pte. Ltd.

Dyne Therapeutics, Inc.

17.56
-0.2400-1.35%
Post-market: 17.560.00000.00%18:03 EDT
Volume:5.06M
Turnover:89.85M
Market Cap:2.90B
PE:-5.05
High:18.84
Open:17.88
Low:17.25
Close:17.80
52wk High:25.00
52wk Low:6.36
Shares:165.03M
Float Shares:152.00M
Volume Ratio:2.04
T/O Rate:3.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4740
EPS(LYR):-3.4740
ROE:-55.71%
ROA:-31.16%
PB:2.98
PE(LYR):-5.05

Loading ...

J.P. Morgan Reaffirms Their Hold Rating on Dyne Therapeutics (DYN)

TIPRANKS
·
Mar 16

Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case

Simply Wall St.
·
Mar 15

Top Dyne Therapeutics Insider Quietly Boosts Stake in Bold New Move

TIPRANKS
·
Mar 14

Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares

Reuters
·
Mar 14

Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data

Simply Wall St.
·
Mar 13

Dyne Therapeutics Director Dirk Kersten Disposes of Common Shares

Reuters
·
Mar 12

Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO) and Dyne Therapeutics (DYN)

TIPRANKS
·
Mar 10

Dyne Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 10

Dyne Therapeutics (DYN) Is Down 8.0% After Advancing Key Neuromuscular Trials Has The Bull Case Changed?

Simply Wall St.
·
Mar 10

Dyne Therapeutics Rises on Positive Data for Duchenne Muscular Dystrophy Treatment

Dow Jones
·
Mar 10

Stock Track | Dyne Therapeutics Soars 5.18% Intraday on Phase 3 Trial Launch and Positive Clinical Data

Stock Track
·
Mar 09

Dyne Therapeutics announces data from Phase 1/2 Deliver trial of z-rostudirsen

TIPRANKS
·
Mar 09

Dyne Therapeutics launches Phase 3 HARMONIA trial of z-basivarsen in DM1

Reuters
·
Mar 09

Dyne reports positive 24-month cardiopulmonary results for z-rostudirsen in DELIVER DMD trial

Reuters
·
Mar 09

Dyne Therapeutics Announces New Positive Cardiopulmonary Results From Deliver Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (Dmd)

THOMSON REUTERS
·
Mar 09

Dyne Therapeutics Inc - 24-Month Data Show Improved Heart and Lung Function With Z-Rostudirsen in Dmd

THOMSON REUTERS
·
Mar 09

Dyne Therapeutics Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 04

Stock Track | Dyne Therapeutics Plummets 5.08% Intraday Following Analyst Price Target Cuts

Stock Track
·
Mar 03

Dyne Therapeutics (DYN) Gets a Buy from RBC Capital

TIPRANKS
·
Mar 03

Dyne Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 03